Should we redefine treatment targets in rheumatoid arthritis? Low disease activity is sufficiently strict for patients who are anticitrullinated protein antibody-negative

Journal of Rheumatology

Volumn 40, Issue 8, 2013, Pages 1268-1274

  De Punder, Yvonne M R ^a   Hendrikx, Jos ^a   Den Broeder, Alfons A ^b   Pascual, Elia Valls ^a   Van Riel, Piet L ^a   Fransen, Jaap ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Department of Rheumatology   (Netherlands)

Author keywords

Anticitrullinated protein antibody; Inflammation; Joint erosions; Rheumatoid arthritis

Indexed keywords

CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ACTIVITY SCORE; DISEASE COURSE; DISEASE DURATION; DRUG INDICATION; DRUG RESPONSE; DRUG TARGETING; FEMALE; HUMAN; JOINT INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS;

ANTICITRULLINATED PROTEIN ANTIBODY; INFLAMMATION; JOINT EROSIONS; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; BLOOD SEDIMENTATION; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PEPTIDES, CYCLIC; PROGNOSIS; RETROSPECTIVE STUDIES; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84881403873     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.121438     Document Type: Article

References (31)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2010;69:631-7.
2. McInnes IB, Schet G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011;365:2205-19.
3. Van der Heijde DM. Joint erosions and patients with early rheumatoid arthritis. Br J Rheumatol 1995;34 Suppl 2:74-8.
4. Keystone EC, Smolen J, van Riel P. Developing an effective treatment algorithm for rheumatoid arthritis. Rheumatology 2012;51 Suppl 5:48-54.
5. Smolen JS, Landewé R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010;69:964-75.
6. Combe B, Landewé R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
7. Machold KP, Stamm TA, Nell VP, Pflugbeil S, Aletaha D, Steiner G, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology 2007;46:342-9.
8. Courvoisier N, Dougadous M, Cantagrel A, Goupille P, Meyer O, Sibilia J, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: A prospective study. Arthritis Res Ther 2008;10:R106.
9. Syversen SW, Gaarder PI, Goll GL, Odegard S, Haavardsholm EA, Mowinckel P, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-7.
10. Van der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
11. Kastbom A, Strandberg G, Lindroos A, Skogh T. Anti-CCP antibody test predicts the disease course during 3 years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004;63:1085-9.
12. Schipper LG, Fransen J, Den Broeder AA, van Riel P. Time to achieve remission determines time to be in remission. Arthritis Res Ther 2010;12:R97.
13. Heiberg T, Kvien TK, Mowinckel P, Aletaha D, Smolen JS, Hagen KB. Identification of disease activity and health status cutoff points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis 2008;67:967-71.
14. Leeb BF, Andel I, Leder S, Leeb A, Rintelen B. The patient's perspective and rheumatoid arthritis disease activity indexes. Rheumatology 2005;44:360-5.
15. Schmitz MK, Guedes LN, Costa LP, Macedo PA, Caldas CAM, Medeinos DM, et al. Evaluation of patients acceptable symptom state (PASS) in a Brazilian cohort of patients with rheumatoid arthritis. Ann Rheum Dis 2008;67 Suppl 3:437.
16. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol Suppl. 2004 Mar;69:14-21.
17. Marotte H, Miossec P. Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNF-alpha therapy. Biologics 2008;2:663-9.
18. Smolen JS, Avila JC, Aletaha D. Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: dissociation of the link between inflammation and destruction. Ann Rheum Dis 2012;71:687-93.
19. van der Heijde DM, van't Hof MA, van Riel PL, Theunisse LA, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
20. Rau R, Wassenberg S, Herborn G, Stucki G, Gebler A. A new method of scoring radiographic change in rheumatoid arthritis. J Rheumatol 1998;25:2094-107.
21. Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. Ann Rheum Dis 2009;68:1535-40.
22. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol 2006;59:1087-91.
23. Aletaha D, Alasti F, Smolen JS. Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. Ann Rheum Dis 2012 Jul 13. [E-pub ahead of print]
24. de Punder YM, Fransen J, Kievit W, Houtman PM, Visser H, van de Laar MA, et al. The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 2012;51:1610-7.
25. Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H, et al. Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 2011;70:812-7.
26. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very low-dose prednisolone in early rheumatoid arthritis retards radiographic progression over two years. A multicentre, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:3371-80.
27. Rau R, Wassenberg S. Scoring methods. J Rheumatol 2002; 29:653-5.
28. Tanaka E, Yamanako H, Matsuda Y, Urano W, Nakajima H, Taniguchi A, et al. Comparison of the Rau method and the Larsen method in the evaluation of radiographic progression in early rheumatoid arthritis. J Rheumatol 2002;29:682-7.
29. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. Ann Rheum Dis 2001;60:817-27.
30. Welsing PM, Fransen J, van Riel P. Is the disease course of rheumatoid arthritis becoming milder? Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005;52:2616-24.
31. Uhlig T, Kvien TK. Is rheumatoid arthritis really getting less severe? Nat Rev Rheumatol 2009;5:461-4.